Every S-1 that TRADEWINDS UNVL (TRWD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow TRWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRWD filings page.
Tradewinds Universal is registering 20,000,000 shares of common stock for resale by RH2 Equity Partners under a committed equity line of credit. These shares relate to a purchase agreement allowing RH2 to buy stock over time.
Tradewinds will not receive proceeds from RH2’s resale, but may raise up to $10,000,000 by selling newly issued shares to RH2 after effectiveness. Shares outstanding could rise from 42,690,580 as of December 31, 2025 to 62,690,580 if all registered shares are issued. The company reports modest 2025 revenue of $133,222, a net loss of $892,877, and a going concern warning, and is shifting from insect-based nutrition products toward licensing and a potential nightlife and hospitality expansion via a non-binding Peppermint Hippo LOI.
Tradewinds Universal is registering 20,000,000 shares of common stock for resale by RH2 Equity Partners under a committed equity facility. The company itself is not selling shares in this prospectus, but may sell up to $10,000,000 of stock to RH2 at its discretion over 24 months.
As of December 31, 2025, Tradewinds had 42,690,580 shares outstanding and operates edible insect protein products and a licensed canine pain-relief formula, while exploring a nightlife and hospitality expansion via a non-binding Peppermint Hippo LOI. 2025 revenue was $133,222, with a net loss of $892,877, and auditors have raised substantial doubt about its ability to continue as a going concern.
The filing highlights very early-stage operations, heavy reliance on CEO Andrew Read, liquidity risk, penny-stock trading on OTCMarkets under “TRWD,” and the potential for significant dilution and price pressure as RH2 resells shares purchased at a discount to market.
Tradewinds Universal has filed an S-1 to register the resale of up to 20,000,000 shares of common stock by RH2 Equity Partners under a committed equity facility. The company itself is not selling shares in this prospectus, but may raise up to $10,000,000 by selling stock to RH2 at its discretion under a separate purchase agreement.
As of January 29, 2026, Tradewinds had 43,690,580 common shares outstanding, trading on OTCMarkets under the symbol TRWD at $0.10 per share. The company is an early-stage holding company built around insect-protein nutrition products and a canine pain-relief formula, and has signed a letter of intent to expand into nightlife and hospitality through Peppermint Hippo-branded venues.
The filing highlights limited operating history, recurring net losses, tight liquidity, dependence on CEO Andrew Read, and significant potential dilution from equity financing. Shares are classified as penny stock, which can reduce trading liquidity and make it harder for investors to resell their holdings.